



Research Collaboration Presents Significant Findings at Conference in Prague, Czech Republic

Edmond, OK (January 5, 2007): The M.D. Anderson Cancer Center (MDACC)/NanoBioMagnetics, Inc. (NBMI) research collaboration recently presented highly significant findings on site-specific delivery of chemotherapeutics at the annual combined meeting of the European Organization for Research and Treatment of Cancer (EORTC), American Association for Cancer Research (AACR), and the National Cancer Institute (NCI) in Prague, Czech Republic.

Dr. Jim Klostergaard, Professor of Molecular and Cellular Oncology at the M. D. Anderson Cancer Center presented a paper titled "Magnetic Localization of Magnetically-Responsive Nanoparticles to Human Ovarian Carcinoma Peritoneal Xenografts."

According to Dr. Klostergaard, "These results demonstrate, both by magnetic resonance imaging (MRI) and tissue histology criteria, that we are able to magnetically vector systemically-administered, magnetically-responsive nanoparticles to a human ovarian tumor xenograft. This is the first such positive localization study, and distinguishes our approach from those of other international research groups." Co-authors on the paper include Dr. Jim Bankson, MDACC, and Dr. William Yuill and Charles Seeney of NBMI.

This paper follows recent publications by the research team at the 6th Annual International Conference on Magnetic Carriers in Krems, Austria. The EORTC/AACR/NCI Conference is a unique and internationally recognized forum for the exchange of information on advances in early drug development in the treatment of cancer. This 18th conference, entitled "Molecular Targets and Cancer Therapeutics", covered the entire spectrum of early drug development. Special attention was given to the preclinical/clinical interphase discussing preclinical and Phase I trials. The conference was designed to ensure maximum interaction and discussion between scientists, clinicians and those involved in drug development.

"I was surprised that most of the researchers working on site-specific delivery are still in the *in vitro* phase of their studies," say Klostergaard. "Our collaboration has been *in vivo* for nearly a year and will enter a critical phase of our preclinical trials soon after the first of the year."

Based on successful vectoring results in the ovarian model, the NBMI/MDACC research team will follow with localization studies in other tumor models, moving to efficacy studies with drug-loaded nanoparticles.

"We have successfully developed a number of constructs linking chemotherapeutics to magnetically responsive nanoparticles," says Charles Seeney, President and CEO of NBMI. "Knowing that we can successfully deliver nanoparticles in a site-specific manner, I'm very optimistic that our constructs will be able to deliver a chemotherapeutic load to affected tissues. Killing a tumor using our technology will be a watershed event, bringing us to step closer to one of the 'holy grails' of medicine."

Contact: Dennis Donaldson

Safe Harbor Statement

Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.